These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31094083)

  • 41. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
    Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
    Kotaka M; Iwamoto S; Satake H; Sakai D; Kudo T; Fukunaga M; Konishi K; Ide Y; Ikumoto T; Tsuji A; Sano Y; Kato T; Sugimoto N; Satoh T; Kanazawa A; Kurata T; Yamanaka T; Tomita N
    Int J Clin Oncol; 2020 Aug; 25(8):1515-1522. PubMed ID: 32409917
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of muscle mass using chest computed tomography-based quantitative and qualitative measurements in patients with systemic sclerosis: A retrospective study with cross-sectional and longitudinal analyses.
    da Rocha DS; Tessari JA; Mainardi NB; Hax V; Gasparin AA; de Oliveira CAV; Garcia TS; Xavier RM; Chakr RMDS
    Semin Arthritis Rheum; 2023 Apr; 59():152168. PubMed ID: 36736023
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The relationship between computed tomography-derived body composition, systemic inflammatory response, and survival in patients undergoing surgery for colorectal cancer.
    Dolan RD; Almasaudi AS; Dieu LB; Horgan PG; McSorley ST; McMillan DC
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):111-122. PubMed ID: 30460764
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of DPYD*9A, DPYD*6 and GSTP1 ile105val Genetic Polymorphisms on Capecitabine and Oxaliplatin (CAPOX) Associated Toxicities in Colorectal Cancer (CRC) Patients.
    Varma K A; Jayanthi M; Dubashi B; Shewade DG
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):3093-3100. PubMed ID: 31653159
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thoracic skeletal muscle index is effective for CT-defined sarcopenia evaluation in patients with head and neck cancer.
    Vangelov B; Smee R; Moses D; Bauer J
    Eur Arch Otorhinolaryngol; 2023 Dec; 280(12):5583-5594. PubMed ID: 37573279
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experience.
    Zilioli VR; Albano D; Arcari A; Merli F; Coppola A; Besutti G; Marcheselli L; Gramegna D; Muzi C; Manicone M; Camalori M; Ciammella P; Colloca G; Tucci A
    J Cachexia Sarcopenia Muscle; 2021 Aug; 12(4):1042-1055. PubMed ID: 34114749
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CT-determined low skeletal muscle index predicts poor prognosis in patients with colorectal cancer.
    Feng Y; Cheng XH; Xu M; Zhao R; Wan QY; Feng WH; Gan HT
    Cancer Med; 2024 Jun; 13(12):e7328. PubMed ID: 38924332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
    Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy.
    Regnier P; DE Luca V; Brunelle S; Sfumato P; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Durand M; Gravis G; Pignot G
    Minerva Urol Nephrol; 2021 Apr; 73(2):215-224. PubMed ID: 32083413
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer.
    Blauwhoff-Buskermolen S; Versteeg KS; de van der Schueren MA; den Braver NR; Berkhof J; Langius JA; Verheul HM
    J Clin Oncol; 2016 Apr; 34(12):1339-44. PubMed ID: 26903572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of muscle mass loss on outcomes in advanced or metastatic gastric cancer patients receiving a second-line treatment.
    Zurlo V; Rosa F; Rinninella E; Pontolillo L; Beccia V; Maratta M; Tortora G; Alfieri S; Pozzo C; Strippoli A
    Eur Rev Med Pharmacol Sci; 2024 Feb; 28(4):1575-1584. PubMed ID: 38436190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer.
    Derksen JWG; Kurk SA; Peeters PHM; Dorresteijn B; Jourdan M; van der Velden AMT; Nieboer P; de Jong RS; Honkoop AH; Punt CJA; Koopman M; May AM
    J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):919-928. PubMed ID: 32107889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Significance of sarcopenia as a prognostic factor for metastatic urothelial carcinoma patients treated with systemic chemotherapy.
    Abe H; Takei K; Uematsu T; Tokura Y; Suzuki I; Sakamoto K; Nishihara D; Yamaguchi Y; Mizuno T; Nukui A; Kobayashi M; Kamai T
    Int J Clin Oncol; 2018 Apr; 23(2):338-346. PubMed ID: 29098519
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
    Sato Y; Ohnuma H; Hirakawa M; Takahashi M; Osuga T; Okagawa Y; Murase K; Takada K; Kawano Y; Iyama S; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Okita K; Mizuguchi T; Furuhata T; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):587-94. PubMed ID: 25577134
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
    Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
    Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer.
    Williams GR; Deal AM; Shachar SS; Walko CM; Patel JN; O'Neil B; McLeod HL; Weinberg MS; Choi SK; Muss HB; Sanoff HK
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):413-417. PubMed ID: 29159476
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).
    Sasaki S; Oki E; Saeki H; Shimose T; Sakamoto S; Hu Q; Kudo K; Tsuda Y; Nakashima Y; Ando K; Akagi Y; Kakeji Y; Baba H; Maehara Y
    Int J Clin Oncol; 2019 Oct; 24(10):1204-1213. PubMed ID: 31062115
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of sarcopenia and acute muscle mass loss on long-term outcomes in critically ill patients with intra-abdominal sepsis.
    Cox MC; Booth M; Ghita G; Wang Z; Gardner A; Hawkins RB; Darden DB; Leeuwenburgh C; Moldawer LL; Moore FA; Efron PA; Anton S; Brakenridge SC
    J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1203-1213. PubMed ID: 34196134
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of sarcopenia on overall survival in patients with pan-RAS wild-type colorectal liver metastasis receiving hepatectomy.
    Yang YR; Shi CS; Chang SW; Wu YY; Su YL; Lin GP; Kuan FC
    Sci Rep; 2023 Apr; 13(1):6911. PubMed ID: 37106073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.